Key facts
- It has raised $34.4M; the latest was Later Stage VC ($18.3M) in May 2024.
- Notable investors include Mirae Asset Capital, Kiwoom Investment, T.S. Investment, DAYLI Partners, Yuanta Investment — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Idience
- ·The full record, as it builds
Funding rounds
No funding rounds for Idience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Idience
Developer of oncology drugs intended to deliver breakthroughs that drive innovation and transform cancer treatment. The company's drug is a potent inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promotes the conversion of SSB to double-stranded breaks, which ultimately leads to synthetic lethality in cancer cells, enabling cancer patients by targeting multiple solid tumors as monotherapy and for combination with other anti-cancer agents.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 20
- Website
- idience.com/
- Ownership
- Privately Held (backing)
Idience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Idience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Idience in its N-PORT filings yet. We sweep new filings monthly.